Searched for
GSK GROUP
Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...- $10. 6 billion deal: GSK to buy US cancer specialist NuvalentBritish pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in c...
- US stocks: US market rises as tech shares gain, Middle East tensions easeWall Street indexes opened higher on Tuesday, driven by a second consecutive day of gains for chipmakers. Easing Middle East tensions also ...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premiumInvestors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...
- Dividends, bonus issues: TCS, LIC, Bajaj Auto among 30 stocks turning ex-date this week. Check detailsInvestors must hold shares of these companies in their demat accounts on the record date to be eligible for the respective corporate action...
- Experimental pancreatic cancer drug appears to dramatically improve one year survival ratesA groundbreaking study published in Nature Medicine reveals that the experimental drug Elraglusib, when combined with standard chemotherapy...
- On their toes: Brands step up anti-counterfeit drive as fake products flood marketsCompanies are fighting a rising tide of fake goods. Brands from toothpaste to cigarettes are changing packaging and tightening checks. Coun...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapyBritain's GSK is set to acquire RAPT Therapeutics for $2.2 billion. This move brings the experimental food allergy drug ozureprubart into G...
- GlaxoSmithKline Pharma names Bhushan Akshikar as new Managing DirectorBefore joining GSK, Akshikar spent 15 years with Janssen, Johnson & Johnson in various roles leading both specialty and primary care busine...
- GSK India appoints Bhushan Akshikar as managing directorAkshikar with over 26 years experience within the pharmaceutical industry, joined GSK India in September 2011 to lead the specialty and com...
- Govt clears GlaxoSmithKline's Rs 6,400 crore FDI proposalThe Cabinet Committee on Economic Affairs has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 per ...
- GSK gets FIPB nod to buy 24.33% more in indian armThe Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33%stake, or 2.06 crore, equity shares in GlaxoSmithKline Pharmace...
- GlaxoSmithKline to spend $1 billion to raise stake in Indian pharma unitGSK said that it was looking to buy a 24% stake in the pharmaceuticals subsidiary for about $1billion or Rs 6,400 crore.
- GlaxoSmithKline emerging markets head sent to handle China crisis: SourceGlaxoSmithKline has sent its head of emerging markets to China to lead the drugmaker's response to an unfolding crisis over alleged bribery...
- GlaxoSmithKline buys US skincare firm Stiefel for $3.6 bnBritish drugs firm GlaxoSmithKline (GSK) said Monday it will buy Stiefel Laboratories, US maker of anti-itching creams, acne treatments and...
- Ranbaxy starts study on new respiratory inflammation medicineIndia's largest drugmaker Ranbaxy Laboratories has started initial clinical studies (Phase I) on the lead compound to develop a new respira...
- Tatas exit Sitel, get $22.2 mTata Consultancy Services is exiting its joint venture BPO, Sitel India, by selling its 40% stake for $17.73 million to Sitel Corporation.
- GSK to offer $15 bn for Pfizer unit: reportThe British-based pharmaceutical group GlaxoSmithKline (GSK) is planning to offer more than $15 billion dollars for the consumer health car...
Load More
